# BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

> **NCT03315520** · PHASE2 · UNKNOWN · sponsor: **State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed/Refractory Malignant Lymphomas

## Interventions

- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT03315520
- **Lead sponsor:** State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-22
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315520, "BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03315520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*